drugset / Trial / NCT05103683
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Phase 1
Recruiting
90 enrolled
TORL Biotherapeutics, LLC
Translational Research in Oncology · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
Timeline
- Start
- 2021-11-17
- Primary completion
- 2026-08-31
- Completion
- 2026-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TORL-1-23 | Other / unclassified | — | — |